ArticleChinese medical journal2026
Oncogenic DNMT3B as a therapeutic target for cervical cancer.
Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpigenetic-related genes (ERGs) play a pivotal role in cancer development and progression. However, their potential for cervical cancer (CC) diagnosis and prognosis remains underexplored.
methodsClinical data and gene expression profiles were sourced from publicly available databases. Epigenetic associations were predicted using the least absolute shrinkage and selection operator (LASSO) Cox regression model, and multiple algorithms were employed to evaluate the impact of ERGs on immune responses, treatment outcomes, and predictive accuracy. Western blotting analysis and quantitative real-time polymerase chain reaction were used to assess gene expression. Subsequently, DNMT3B was selected for further in vitro and in vivo study.
resultsA total of 567 ERGs were identified from open-access databases, with 59 found to be significantly associated with prognosis of CC. Five ERGs ( DNMT3B , SMYD2 , IKZF3 , L3MBTL2 , and CHD7 ) were deemed instrumental in constructing a prognostic signature for CC. The predictive accuracy of the ERG signature was evaluated, revealing a robust correlation between immune cell infiltration, immunotherapy response, drug sensitivity, and the ERG signature. DNMT3B was found to be highly expressed in CC, and both in vitro and in vivo experiments confirmed its role in promoting tumor growth.
conclusionsThe epigenetic signature developed in this study holds considerable promise for prognostic prediction and therapeutic guidance in patients with CC. DNMT3B was identified as an oncogenic gene, highlighting its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.